Scancell Hldgs Plc (SCLP) - Cash Flow Conversion Efficiency

Latest as of October 2025: 0.846x

Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has a cash flow conversion efficiency ratio of 0.846x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.08 Million ≈ $-861.55 USD) by net assets (GBX-8.37 Million ≈ $-1.02K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Scancell Hldgs Plc - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Scancell Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SCLP current and long-term liabilities for a breakdown of total debt and financial obligations.

Scancell Hldgs Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scancell Hldgs Plc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Binakarya Jaya Abadi Tbk PT
JK:BIKA
-0.043x
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
0.074x
Hedera Group publ AB
ST:HEGR
0.022x
C3is Inc.
NASDAQ:CISS
0.031x
Bastion Minerals Ltd
AU:BMO
-0.347x
Melar Acquisition Corp. I Warrant
NASDAQ:MACIW
N/A
Cathedra Bitcoin Inc
V:CBIT
-0.068x
Baiya International Group Inc. Ordinary Shares
NASDAQ:BIYA
N/A

Annual Cash Flow Conversion Efficiency for Scancell Hldgs Plc (2009–2025)

The table below shows the annual cash flow conversion efficiency of Scancell Hldgs Plc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Scancell Hldgs Plc stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-04-30 GBX-3.83 Million
≈ $-466.61
GBX-6.11 Million
≈ $-742.92
1.592x -64.36%
2024-04-30 GBX-3.50 Million
≈ $-426.46
GBX-15.66 Million
≈ $-1.91K
4.468x +242.12%
2023-04-30 GBX-6.23 Million
≈ $-758.38
GBX-8.14 Million
≈ $-990.40
1.306x +426.11%
2022-04-30 GBX19.48 Million
≈ $2.37K
GBX-7.80 Million
≈ $-949.40
-0.400x +60.75%
2021-04-30 GBX7.65 Million
≈ $930.54
GBX-7.80 Million
≈ $-949.40
-1.020x -35.45%
2020-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.03 Million
≈ $-855.71
-0.753x -0.21%
2019-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.02 Million
≈ $-853.88
-0.752x -157.92%
2018-04-30 GBX13.94 Million
≈ $1.70K
GBX-4.06 Million
≈ $-494.32
-0.291x +50.77%
2017-04-30 GBX6.50 Million
≈ $790.78
GBX-3.85 Million
≈ $-468.13
-0.592x -153.79%
2016-04-30 GBX9.99 Million
≈ $1.22K
GBX-2.33 Million
≈ $-283.58
-0.233x +40.30%
2015-04-30 GBX6.75 Million
≈ $821.77
GBX-2.64 Million
≈ $-321.06
-0.391x -69.41%
2014-04-30 GBX9.08 Million
≈ $1.10K
GBX-2.09 Million
≈ $-254.70
-0.231x +41.23%
2013-04-30 GBX5.09 Million
≈ $619.57
GBX-2.00 Million
≈ $-243.14
-0.392x -418.26%
2012-04-30 GBX6.97 Million
≈ $848.21
GBX859.62K
≈ $104.59
0.123x +132.17%
2011-04-30 GBX4.64 Million
≈ $564.07
GBX-1.78 Million
≈ $-216.21
-0.383x -76.43%
2010-04-30 GBX6.05 Million
≈ $735.87
GBX-1.31 Million
≈ $-159.88
-0.217x -7.79%
2009-04-30 GBX5.25 Million
≈ $639.26
GBX-1.06 Million
≈ $-128.85
-0.202x --

About Scancell Hldgs Plc

LSE:SCLP UK Biotechnology
Market Cap
$1.91 Million
GBX15.67 Billion GBX
Market Cap Rank
#29735 Global
#688 in UK
Share Price
GBX15.10
Change (1 day)
+7.86%
52-Week Range
GBX8.54 - GBX15.10
All Time High
GBX27.50
About

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more